Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731326 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL1244093 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL4722847 | 0.80 | ALDH1A1 (0.44) | EPHX1 | |
| SCHEMBL1243340 | 0.78 | — | — | |
| SCHEMBL731075 | 0.78 | — | — | |
| SCHEMBL9009859 | 0.75 | HTT (0.37) | — | |
| SCHEMBL21486265 | 0.75 | — | — | |
| SCHEMBL731466 | 0.73 | CYP2C19 (0.34) | — | |
| SCHEMBL4599392 | 0.71 | NR1H2 (0.36) | EPHX1 | |
| SCHEMBL1162997 | 0.70 | BTK (0.36) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138164-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | EPHX1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.